METHODS: Both trials compared treatments using prandial insulins (aspart or lispro) three times daily with more classical insulin strategies using basal insulin given once daily (glargine or detemir) or twice daily if required (detemir in the 4-T Study). RESULTS/CONCLUSION: Both studies showed ...
Thus, for evidence of recovery of glucotoxicity-associated β-cell dysfunction, we sought to determine whether there exists a baseline fasting glucose threshold above which the post-IIT improvement in both β-cell function and glycemia is amplified.RESEARCH DESIGN AND METHODSIIT (glargine, lispro) ...
The cornerstone of T1D management is subcutaneous insulin administration, aiming to substitute the deficient hormone and achieve optimal blood glucose levels [6]. Various insulin formulations and delivery systems have been developed, including rapid-acting (e.g., lispro, aspart, glulisine), short-...